Rotarix™ (RIX4414): an oral human rotavirus vaccine

References

• Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg. Infect. Dis.9, 565–572 (2003).
   PubMed Web of Science ®Google Scholar
• Parashar UD, Gibson CJ, Bresse JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg. Infect. Dis.12, 304–306 (2006).
   PubMed Web of Science ®Google Scholar
• Velazquez FR, Matson DO, Calva JJ et al. Rotavirus infection in infants as protection against subsequent infections. N. Engl. J. Med.335, 1022–1028 (1996).
   PubMed Web of Science ®Google Scholar
• O’Ryan M, Pérez-Schael I, Mamani N et al. Rotavirus-associated medical visits and hospitalizations in South America: a prospective study at three large sentinel hospitals. Pediatr. Infect. Dis. J.20, 685–693 (2001).
   PubMed Web of Science ®Google Scholar
• Tucker AW, Haddix AC, Bresee JS, Holman RC, Parashar UD, Glass RI. Cost-effectiveness analysis of a rotavirus immunization program for the United States. JAMA279, 1371–1376 (1998).
   PubMed Web of Science ®Google Scholar
• Parashar UD, Holman RC, Clarke MJ, Bresee JS, Glass RI. Hospitalizations associated with rotavirus diarrhea in the United States, 1993 through 1995: surveillance based on the new ICD-9-CM rotavirus-specific diagnostic code. J. Infect. Dis.177, 13–17 (1997).
   Web of Science ®Google Scholar
• Charles MD, Holman RC, Curns AT, Parashar UD, Glass RI, Bresee JS. Hospitalizations associated with rotavirus gastroenteritis in the United States, 1993 –2002. Pediatr. Infect. Dis. J.25, 489–493 (2006).
   PubMed Web of Science ®Google Scholar
• Malek MA, Curns AT, Holman RC et al. Diarrhea- and rotavirus-associated hospitalizations among children less than 5 years of age: United States, 1997 and 2000. Pediatrics117, 1887–1892 (2006).
   PubMed Web of Science ®Google Scholar
• Black RE, Morris SS, Bryce J. Where and why are 10 million children dying every year? Lancet361, 2226–2234 (2003).
   PubMed Web of Science ®Google Scholar
• Kosek M, Bern C, Guerrant RL. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull. World Health Organ.81, 197–204 (2003).
   PubMed Web of Science ®Google Scholar
• WHO. Rotavirus vaccines, an update. Wkly Epidemiol. Rec.78, 2–3 (2003).
   PubMedGoogle Scholar
• Glass RI, Parashar UD, Bresee JS et al. Rotavirus vaccines: current prospects and future challenges. Lancet368(9532), 323–332 (2006).
   PubMed Web of Science ®Google Scholar
• Matson DO, O’Ryan ML, Jiang X, Mitchell DK. Rotavirus, enteric adenoviruses, caliciviruses, astroviruses, and other viruses causing gastroenteritis. In: Clinical Virology Manual (3rd Edition). Spector S, Hodinka RL, Young SA (Eds). ASM Press, Washington DC, USA, 270–294 (2000).
   Google Scholar
• Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev. Med. Virol.5, 29–56 (2005).
   Web of Science ®Google Scholar
• Gentsch JR, Woods PA, Ramachandran M et al. Review of G and P typing results from a global collection of rotavirus strains: implications for vaccine development. J. Infect. Dis.74(Suppl. 1), S30–S36 (1996).
   Google Scholar
• Unicomb L, Podder G, Gentsch J et al. Evidence of high-frequency genomic reassortment of group A rotavirus strains in Bangladesh: emergence of type G9 in 1995. J. Clin. Microbiol.37, 1885–1891 (1999).
   PubMedGoogle Scholar
• Banyai K, Gentsch JR, Schipp R et al. Dominating prevalence of P(8),G1 and P(8),G9 rotavirus strains among children admitted to hospital between 2000 and 2003 in Budapest, Hungary. J. Med. Virol.76, 414–123 (2005).
   PubMed Web of Science ®Google Scholar
• Rahman M, Matthijnssens J, Goegebuer T et al. Predominance of rotavirus G9 genotype in children hospitalized for rotavirus gastroenteritis in Belgium during 1999–2003. J. Clin. Virol.33, 1–6 (2005).
   PubMedGoogle Scholar
• Ramachandran M, Das B, Vij A et al. Unusual diversity of human rotavirus G and P genotypes in India. J. Clin. Microbiol.34, 436–439 (1996).
   PubMed Web of Science ®Google Scholar
• Santos N, Lima R, Pereira C, Gouvea V. Detection of rotavirus types G8 and G10 among Brazilian children with diarrhea. J. Clin. Microbiol.36, 2727–2729 (1998).
   PubMedGoogle Scholar
• O’Ryan ML, Matson DO, Estes MK, Pickering LK. Molecular epidemiology of rotavirus in children attending day care centers in Houston. J. Infect. Dis.162, 810–816 (1990).
   PubMedGoogle Scholar
• Bishop RF, Barnes GL, Cipriani E, Lund JS. Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. N. Engl. J. Med.309, 72–76 (1983).
   PubMed Web of Science ®Google Scholar
• O’Ryan ML, Matson DO, Pickering LK, Estes MK. Anti-rotavirus G type-specific and isotype-specific antibodies in children with natural rotavirus infections. J. Infect. Dis.169, 504–511 (1994).
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Glass RI, Rodgers G, Davidson BL, Sack DA. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. JAMA273(15), 1191–1196 (1995).
   PubMed Web of Science ®Google Scholar
• Santosham M, Moulton LH, Reid R et al. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. J. Pediatr.131, 632–638 (1997).
   PubMed Web of Science ®Google Scholar
• Perez-Schael I, Guntinas MJ, Perez M et al. Efficacy of the rhesus-based quadrivalent vaccine in infants and young children in Venezuela. N. Engl. J. Med.337, 1181–1187 (1997).
   PubMed Web of Science ®Google Scholar
• Joensuu J, Koskenniemie E, Pang XL, Vesikari T. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet350, 1205–1209 (1997).
   PubMed Web of Science ®Google Scholar
• Rennels MB, Glass RI, Dennehy PH et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines: report of the national multicenter trial. Pediatrics97, 7–13 (1996).
   PubMed Web of Science ®Google Scholar
• Murphy TV, Gargiullo PM, Massoudi MS et al. Intussusception among infants given an oral rotavirus vaccine. N. Engl. J. Med.344, 564–572 (2001).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Matson DO, Dennehy P et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N. Engl. J. Med.354, 23–33 (2006).
   PubMed Web of Science ®Google Scholar
• Bernestein DI, Ward RL. Rotarix: development of a live attenuated monovalent human rotavirus vaccine. Pediatr. Ann.35, 38–43 (2006).
   PubMedGoogle Scholar
• Bernstein DI, Smith VE, Sherwood JR et al. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89–12. Vaccine16(4), 381–387 (1998).
   Google Scholar
• Commission for the European Communities. Granting marketing authorization under Regulation [EC] n° 726/2004 of the European Parliament and of the Council for “Rotarix – RV vaccine, live”, a medicinal product for human use; Brussels, 21–II-2006; C[2006]602.
   Google Scholar
• Vesikari T, Karvonen A, Korhonen T et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine22, 2836–2842 (2004).
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Sack DA, Rothstein E et al. Efficacy of live, attenuated, human rotavirus vaccine 89–12 in infants: a randomized placebo-controlled trial. Lancet354, 287–290 (1999).
   PubMedGoogle Scholar
• Bernstein DI, Sack DI, Reisinger K, Rothstein E, Ward R. Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89–12 in healthy infants. J. Infect. Dis.186, 1487–1489 (2002).
   Google Scholar
• Dennehy PH, Brady RC, Halperin SA et al. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. Pediatr. Infect. Dis. J.24, 481–488 (2005).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Puustinen L et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr. Infect. Dis. J.23(10), 937–943 (2004).
   PubMed Web of Science ®Google Scholar
• Salinas B, Pérez Schael I, Linhares A et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414. Pediatr. Infect. Dis. J.24(9), 807–816 (2005).
   PubMed Web of Science ®Google Scholar
• Phua KB, Quak SH, Lee BW et al. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled Phase II trial involving 2464 Singaporean infants. J. Infect. Dis.192, S6–S16 (2005).
   PubMed Web of Science ®Google Scholar
• Ruiz-Palacios GM, Perez-Schael I, Velazquez FR et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N. Engl. J. Med.354, 11–22 (2006).
   PubMed Web of Science ®Google Scholar
• Velásquez FR, Abate A, Bouckenooghe A et al. RIX4414, the human G1P(8) rotavirus vaccine is highly efficacious during the second year of life. International Conference on Antimicrobials and Chemotherapy – ICAAC. CA, USA, September 27–30, 2006.
   Google Scholar
• Vesikari T, Karvonen A, Prymula R et al. Human rotavirus vaccine Rotarix™ (RIX4414, is highly efficacious in Europe). 24th Annual Meeting of the European Society for Pediatric Infectious Diseases-ESPID. Basel, Switzerland, May 3–5, 2006.
   Google Scholar
• Vesikari T, Prymula R, Schuster V et al.Rotarix™ (RIX4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with diphtheria-tetanus-pertussis (DTPa)-combined vaccines in healthy infants from Europe. 24th Annual Meeting of the European Society for Pediatric Infectious Diseases-ESPID. Basel, Switzerland, May 3–5, 2006.
   Google Scholar
• Vesikari T, Karvonen A, Prymula R et al.Rotarix™ (RIX4414), an oral human rotavirus vaccine, is highly immunogenic in healthy infants from 6 European countries. 24th Annual Meeting of the European Society for Pediatric Infectious Diseases-ESPID. Basel, Switzerland, May 3–5, 2006.
   Google Scholar
• Tejedor JC, Díez-Delgado J, Arístegui J et al.Rotarix™ (RIX4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with a Neisseria meningitidis serogroup C vaccine (Meningetec™) in healthy infants from Spain. 24th Annual Meeting of the European Society for Pediatric Infectious Diseases-ESPID. Basel, Switzerland, May 3–5, 2006.
   Google Scholar
• Schuster V, Otto W, Cohen R et al.Rotarix™ (RIX4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with Streptococcus pneumoniae conjugate vaccine (Prevenar™) in healthy infants from France and Germany. 24th Annual Meeting of the European Society for Pediatric Infectious Diseases-ESPID. Basel, Switzerland, May 3–5, 2006.
   Google Scholar
• López P, Linhares A, Pérez-Schael I et al. Early protection against severe rotavirus gastroenteritis-RIX4414 experience in Latin America. 24th Annual Meeting of the European Society for Pediatric Infectious Diseases-ESPID. Basel, Switzerland, May 3–5, 2006.
   Google Scholar
• Vesikari T, Prymula R, Schuster V et al. Early protection against rotavirus, Rotarix™ (RIX4414) experience in a European setting. Int. J. Infect. Dis.10(Suppl. 1), abstract 68.021 (2006).
   Google Scholar
• de Vos B, Gillard P, Cheuvart B, Debrus S, Han H, Bouckenooghe A. RIX4414 vaccine efficacy against rotavirus gastroenteritis due to G2P(4) strain. International Congress on Antimicrobials and Chemotherapy – ICAAC. CA, USA, September 27–30, 2006.
   Google Scholar
• Steele A, Tumbo J, Armah G et al. Concomitant administration of a live-attenuated oral rotavirus vaccine (RIX4414) with poliovirus vaccines in African infants. 23rd Annual Meeting of the European–ESPID. Valencia, Spain, May 18–20, 2005.
   Google Scholar
• Isakbaeva ET, Musabaev E, Antil L et al. Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine. Vaccine25(2), 373–380 (2007).
   PubMed Web of Science ®Google Scholar
• Fischer TK, Anh DD, Antil L et al. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. J. Infect. Dis.192(10), 1720–1726 (2005).
   PubMed Web of Science ®Google Scholar
• Constenla D, O’Ryan M, Navarrete MS, Antil L, Reinghan R. Evaluación de costo-efectividad de la vacuna anti-rotavirus en Chile. Rev. Med. Chile134(6), 679–688 (2006).
   Google Scholar
• Carlin JB, Jackson T, Lane L, Bishop RF, Barnes GL. Cost effectiveness of rotavirus vaccination in Australia. Aust. NZ J. Public Health23(6), 611–616 (1999).
   PubMed Web of Science ®Google Scholar
• Tucker AW, Haddix AC, Bresee JS, Holman RC, Parashar UD, Glass R. Cost-effectiveness analysis of a rotavirus immunization program for the United States. JAMA279(17), 1371–1376 (1998).
   PubMed Web of Science ®Google Scholar